Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284335 · ClinicalTrials.gov registry record · Phase 1
A Safety Study in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 234
- Enrollment target
NCT01284335 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 234 participants.
The verdict
NCT01284335, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 234 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Temozolomide
- DRUG Gemcitabine
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2008-07 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284335
The ClinicalTrials.gov registry entry for NCT01284335 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01284335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01284335 about?
NCT01284335 is a clinical study titled "A Safety Study in Participants With Advanced Solid Tumors". The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associat...
What is the current status of trial NCT01284335?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2008-07. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01284335?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Temozolomide (DRUG), Gemcitabine (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01284335?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.